Cargando…

Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations

OBJECTIVES: To determine the spectrum of infections with multidrug-resistant Gram-negative bacteria (MDR-GNB) and the clinical impact of the newly available betalactam/betalactamase inhibitor combinations ceftolozane/tazobactam and ceftazidime/avibactam in a German academic tertiary care center. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katchanov, Juri, Asar, Lucia, Klupp, Eva-Maria, Both, Anna, Rothe, Camilla, König, Christina, Rohde, Holger, Kluge, Stefan, Maurer, Florian P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896976/ https://www.ncbi.nlm.nih.gov/pubmed/29649276 http://dx.doi.org/10.1371/journal.pone.0195757

Ejemplares similares

Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection
por: Dong, Yuzhu, et al.
Publicado: (2020)

Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors
por: Reddy, Nakita, et al.
Publicado: (2023)

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales
por: Lomovskaya, Olga, et al.
Publicado: (2023)

Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
por: Gibble, Allison M., et al.
Publicado: (2015)

In Vitro and In Vivo Development of a β-Lactam-Metallo-β-Lactamase Inhibitor: Targeting Carbapenem-Resistant Enterobacterales
por: Peters, Byron K., et al.
Publicado: (2023)

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
por: Luci, Giacomo, et al.
Publicado: (2021)

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan
por: Yang, Tsung-Ying, et al.
Publicado: (2020)

Efficacy of Noncarbapenem β-Lactams Compared to Carbapenems for Extended-Spectrum β-Lactamase–Producing Enterobacterales Urinary Tract Infections
por: Anderson, Daniel T, et al.
Publicado: (2022)

Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis
por: Cang, Huai Qin, et al.
Publicado: (2023)

Optimized β-Lactam Therapy Improves Survival in Carbapenem Non-Susceptible Gram-Negative Infections
por: Flynt, Lauren K, et al.
Publicado: (2017)

Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria in vitro and in vivo
por: El Hafi, Bassam, et al.
Publicado: (2019)

Interactions of hydrolyzed β-lactams with the L1 metallo-β-lactamase: Crystallography supports stereoselective binding of cephem/carbapenem products
por: Hinchliffe, Philip, et al.
Publicado: (2023)

Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
por: Lee, Su Young, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients
por: Han, Ruiying, et al.
Publicado: (2021)

Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis
por: Muhammed, Maged, et al.
Publicado: (2017)

2125. Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations against Serine-Carbapenemase producing Carbapenem-Resistant Pseudomonas aeruginosa
por: Lee, Su Young, et al.
Publicado: (2023)

Risk factors for excessively prolonged meropenem use in the intensive care setting: a case-contol study
por: Katchanov, Juri, et al.
Publicado: (2017)

Influence of local epidemiology on the performance of common colistin drug susceptibility testing methods
por: Asar, Lucia, et al.
Publicado: (2019)

BADAN-conjugated β-lactamases as biosensors for β-lactam antibiotic detection
por: Au, Ho-Wah, et al.
Publicado: (2020)

Cryptic β-Lactamase Evolution Is Driven by Low β-Lactam Concentrations
por: Fröhlich, Christopher, et al.
Publicado: (2021)

1053. The β-Lactamase Inhibitor QPX7728 Restores the Activity of β-Lactam Agents against Contemporary Extended-Spectrum β-lactamase (ESBL)-Producing and Carbapenem-Resistant Enterobacterales (CRE) Isolates, Including Isolates Producing Metallo-β-lactamases
por: Lindley, Jill, et al.
Publicado: (2021)

Penicillin-Binding Proteins, β-Lactamases, and β-Lactamase Inhibitors in β-Lactam-Producing Actinobacteria: Self-Resistance Mechanisms
por: Martin, Juan F., et al.
Publicado: (2022)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
por: Aslan, Abdullah Tarık, et al.
Publicado: (2022)

Time-resolved β-lactam cleavage by L1 metallo-β-lactamase
por: Wilamowski, M., et al.
Publicado: (2022)

Synthesis and biological evaluation of novel β-lactam-metallo β-lactamase inhibitors
por: Shungube, Mbongeni, et al.
Publicado: (2023)

Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections
por: Doremus, Casey, et al.
Publicado: (2021)

Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae
por: Luo, Hong, et al.
Publicado: (2021)

Drug Repurposing of the Unithiol: Inhibition of Metallo-β-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections
por: Grigorenko, Vitaly G., et al.
Publicado: (2022)

Clinically Isolated β-Lactam-Resistant Gram-Negative Bacilli in a Philippine Tertiary Care Hospital Harbor Multi-Class β-Lactamase Genes
por: Abordo, Alecks Megxel S., et al.
Publicado: (2023)

The Importance of Porins and β-Lactamase in Outer Membrane Vesicles on the Hydrolysis of β-Lactam Antibiotics
por: Kim, Si Won, et al.
Publicado: (2020)

Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia
por: Lin, Wei-Ting, et al.
Publicado: (2019)

Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae
por: Harris, Patrick N A, et al.
Publicado: (2015)

677. Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested Against Carbapenem-Resistant Enterobacteriaceae (CRE) Isolates
por: Castanheira, Mariana, et al.
Publicado: (2019)

Chemiluminescence Detection of Hydrogen Sulfide Release by β-Lactamase-Catalyzed β-Lactam Biodegradation: Unprecedented Pathway for Monitoring β-Lactam Antibiotic Bacterial Resistance
por: Gholap, Sachin Popat, et al.
Publicado: (2021)

Structural Variabilities in β-Lactamase (blaA) of Different Biovars of Yersinia enterocolitica: Implications for β-Lactam Antibiotic and β-Lactamase Inhibitor Susceptibilities
por: Singhal, Neelja, et al.
Publicado: (2015)

Editorial for the Special Issue: “Targeting β-Lactamases to Fight Bacterial Resistance to β-Lactam Antibiotics”
por: Pozzi, Cecilia
Publicado: (2020)

Quantitative Insights Into β-Lactamase Inhibitor’s Contribution in the Treatment of Carbapenemase-Producing Organisms With β-Lactams
por: Feng, Yanfang, et al.
Publicado: (2021)

β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources
por: Alfei, Silvana, et al.
Publicado: (2022)

Management of clinical infections of Escherichia coli by new β-lactam/β-lactamase inhibitor combinations
por: Kadry, Ashraf Ahmed, et al.
Publicado: (2022)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
por: Duda-Madej, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7jlo14a56rg0ihsg1ks1f51l5b